media – Page 139 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】Which method (protein or nucleic acid) is better for drug resistance monitoring?

Drugdu.com expert’s response: In the context of antimicrobial resistance (AMR) surveillance, the choice between protein-based and nucleic acid-based detection methods primarily depends on specific surveillance needs, target pathogens, experimental conditions, and cost considerations. Below is a detailed comparison of the two detection methods: I. Advantages of Nucleic Acid Detection High Sensitivity: Nucleic acid detection directly targets the genetic material of pathogens, thus exhibiting high sensitivity. For instance, in tuberculosis AMR surveillance, nucleic acid mass spectrometry can be designed and utilized to identify genetic polymorphisms, achieving highly sensitive detection. High Specificity: With specific primers and probes, nucleic acid detection can achieve specific detection of target pathogens, avoiding false positive results. Rapid Detection Speed: With technological advancements, the turnaround time for nucleic acid detection has shortened, enabling rapid diagnosis of pathogens. Broad Application Range: Nucleic acid detection is applicable not only to bacteria but also to viruses, fungi, and other pathogens for ...
- Source: drugdu
- 299
- February 12, 2025
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: I. Accurate Market Insights: AI as Your Detective (1) Quickly Identify Customers and Markets: Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. (2) Monitor Competitors in Real-Time: With DeepSeek, ...
- Source: drugdu
- 490
- February 11, 2025
AI DeepSeek Drugdu Pharma Trade
One medical device enters the priority approval green channel

On February 6th, the Equipment Review Center of the National Medical Products Administration released the results of the priority approval application for medical devices (No. 2 of 2025), and the products of Aoran Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Aoran Biotechnology”) – Mycobacterium tuberculosis complex and rifampicin resistant nucleic acid detection kit (PCR fluorescence probe method) entered the priority approval green channel. It is worth mentioning that this product belongs to the category of medical devices listed in the National Science and Technology Major Special Project, and is also the 7th IVD related product to enter the priority channel this year. Domestic pioneering technology At present, tuberculosis is still one of the most widely spread and lethal infectious diseases in the world. China is the second country with high burden of tuberculosis in the world. The World Health Organization has proposed the action goal of ending the prevalence ...
- Source: drugdu
- 226
- February 11, 2025
Over 130 million US dollars! Henlius and Dr Reddy’s has reached a European and American authorized cooperation on the biosimilar drug of daratumumab

On February 6, 2025, Henlius (2696. HK) announced its partnership with Dr Dr., a wholly-owned subsidiary of Reddy’s Laboratories Reddy’s Laboratories SA has signed an authorization license agreement for the company’s self-developed biosimilar drug HLX15 (recombinant anti-CD38 whole human monoclonal antibody injection). Dr. Reddy’s Laboratories (and its subsidiaries collectively referred to as “Dr. Reddy’s”) is listed on the Mumbai Stock Exchange (stock code: 500124) and the National Stock Exchange of India (stock code: DRREDDY）、 The New York Stock Exchange (stock code: RDY）、 The International Financial Services Centre of the National Stock Exchange of India (stock code: DRREDDY) is listed. Dr. Reddy’s will have exclusive commercial rights to HLX15 subcutaneous and intravenous formulations in the United States and 42 European countries and regions, covering a total of 43 countries and regions. According to the terms of the agreement, Henlius will be responsible for the research and development, production, and commercial supply ...
- Source: drugdu
- 290
- February 11, 2025
Namixin announces completion of Series A financing, focusing on research and development of mRNA vaccines/drugs

On February 10, 2025, Namixin (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Namixin”) announced the completion of its Series A financing. This financing is jointly invested by Chengdu Bio City Guosheng Capital and Enran Venture Capital. The financing funds will mainly be used to promote clinical research of the NR222 project and the development of new projects. The implementation of this round of financing is a recognition of Namixin by the investors and injects strong impetus into the company’s promotion of subsequent clinical research. Namixin was founded in 2021 and registered in Lingang, Shanghai. It is a biotechnology enterprise specializing in the research and development of new vaccines/drugs in the mRNA field. The founding team of the company has a profound research background in the mRNA field and has held important positions in top pharmaceutical research institutions and pharmaceutical companies both domestically and internationally, effectively mastering the core know-how ...
- Source: drugdu
- 257
- February 11, 2025
The vaccination market for middle-aged and elderly people is still waiting to be opened up for the application of another domestically produced herpes zoster vaccine for market launch

The domestic herpes zoster vaccine market is about to enter the “Three Kingdoms Kill”. On the evening of February 9th, Green Bamboo Biotechnology (02480. HK) announced that its application for the marketing of its recombinant herpes zoster vaccine LZ901 has been accepted by the National Medical Products Administration. If successfully launched, this vaccine will become the third herpes zoster vaccine to be launched in China. Currently, there are two herpes zoster vaccines on the market, one of which is a domestically produced vaccine manufactured by BioNTech; One is an imported vaccine, manufactured by GlaxoSmithKline. Herpes zoster is an infectious skin disease caused by the reactivation of varicella zoster virus that has long been lurking in the posterior root ganglia or cranial ganglia of the spinal cord. As people grow older, their physiological and metabolic functions and immune functions gradually decline, and the risk of suffering from infectious diseases such as ...
- Source: drugdu
- 208
- February 11, 2025
Last year, semaglutide sales were nearly $30 billion, and the Chinese market will soon face challenges

Novo Nordisk recently released its 2024 financial report. During the reporting period, Novo Nordisk achieved revenue of 290.403 billion Danish kroner (approximately $42.137 billion, calculated at 1 Danish kroner = $0.1451, the same below), a year-on-year increase of 25%; net profit was 100.988 billion Danish kroner (approximately $14.653 billion), a year-on-year increase of 21%. The total annual revenue of its three semaglutide products was 201.849 billion Danish kroner (approximately $29.288 billion), a year-on-year increase of nearly 40%, approaching the sales of Merck’s “king of medicine” K drug (pembrolizumab) of $29.486 billion in 2024. In 2024, Novo Nordisk’s diabetes and obesity treatment sales achieved revenue of 271.764 billion Danish kroner (about 39.433 billion U.S. dollars), a year-on-year increase of 26%. The growth was mainly driven by the GLP-1 diabetes treatment field and the obesity treatment field. Among them, the sales of GLP-1 diabetes treatment field increased by 21% in Danish kroner, ...
- Source: drugdu
- 619
- February 11, 2025
Hansoh Pharmaceutical’s product Xinyue’s new indication is included in the priority review and approval process by NMPA

On February 10, Hansoh Pharmaceutical (03692) issued an announcement, announcing that its product Xinyue® (inelizumab injection) was included in the priority review and approval process by the National Medical Products Administration (NMPA) on February 8, 2025 for the new indication of treating immunoglobulin G4-related diseases (IgG4-RD) due to the positive results of the global pivotal Phase III trial MITIGATE. Xinyue® signed a license agreement with Viela Bio on May 24, 2019, obtaining exclusive licenses for development and commercialization in mainland China, Hong Kong and Macau. The product was approved for marketing by NMPA on March 14, 2022, and is suitable for adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin 4 (AQP4) antibodies. In January 2023, the product was included in the “National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List” for the first time and was successfully renewed in November 2024. https://finance.eastmoney.com/a/202502103314676122.html
- Source: drugdu
- 239
- February 11, 2025
Luzhu Biotech’s Core Product BLA Application Accepted by China’s National Medical Products Administration

Luzhu Biotech-B (02480) announced that the Biologics License Application (BLA) for its core product, LZ901, has recently been accepted by the National Medical Products Administration (NMPA) of the People’s Republic of China. This milestone marks a significant step forward in the company’s development of a recombinant shingles vaccine (CHO cell). LZ901 is designed to prevent shingles and related complications, including postherpetic neuralgia, in adults aged 40 and above. The vaccine successfully achieved its predefined objectives and delivered expected clinical results in Phase III clinical trials in China. According to the announcement, after the BLA acceptance, the NMPA will conduct technical reviews, clinical trial site inspections, and manufacturing site inspections to assess the feasibility of the application. However, it is important to note that despite the smooth progress of LZ901’s development, the company cannot guarantee the product’s eventual success in development and commercialization. Shareholders and potential investors are advised to exercise ...
- Source: drugdu
- 292
- February 11, 2025
Exclude products with higher quality risks from centralized procurement

In January this year, some experts believed that some centralized procurement drugs may have quality risks of “blood pressure does not drop, anesthetics do not cause sleep, and laxatives do not cause diarrhea”. Relevant departments quickly sent personnel to investigate and understand the situation. Recently, relevant comrades from the medical insurance and drug supervision departments who participated in the investigation accepted media interviews on issues of social concern. Is there a quality problem on the Internet? Regarding the saying that “antihypertensive drugs do not lower blood pressure”. It is reported that the generic drugs of “amlodipine” are not as effective as the original drugs, and the reason is personal medication experience. Ruijin Hospital provided the clinical real-world research results of the comparison between the selected generic drugs and the original drugs in the centralized procurement of amlodipine besylate in which the hospital participated, showing that “for patients with primary hypertension, ...
- Source: drugdu
- 308
- February 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.